



## **European Medicines Agencies Network initiatives**


Lorraine Nolan Chief Executive at Health Products Regulatory Authority (HPRA)



### **European initiatives**











#### **Strategic focus areas:**

- 1. Availability and accessibility of medicines
- 2. Data analytics, digital tools and digital transformation
- 3. Innovation
- 4. Antimicrobial resistance and other emerging health threats
- 5. Supply chain challenges
- 6. Sustainability of the Network and operational excellence

#### Goal 1

Strengthen the availability of medicines to protect the health of EU citizens and animals

#### Goal 2

Optimise the path from development, evaluation through to access via collaboration




## Network Strategy to 2025: Access & Availability Main Areas of Focus





#### **Root cause**

Specific causes for shortages of generics/off-patent products versus products still under patent protection



#### **Prevention and management**

Development of strategies to improve prevention and management of shortages. It also includes identification of and suggestion of areas where changes to EU or national legislation could improve supply

#### **Shortage management**

Enhance approaches to shortages management through improving the coordination of both information, communication and actions taken by MSs

# **Network Strategy to 2025: Access & Availability Aiming for Success**



HMA:

veterinary use

1. Background

Work programme of the HMA/EMA task force on

availability of authorised medicines for human and

Unavailability of medicines in the EU, either because medicines are not marketed or due to suppli disruptions, has been recognised by HMA and EMA as an area of paset concern' affecting all

4 July 2019 EMA/350084/2018 Rev.



**EUROPEAN MEDICINES AGENCY** 

- Network infrastructure and governance in the area of shortages
- Actions mapped with workplans of relevant network committees and working groups

new tasks to the Agency.

- Expanded remit of the EMA
- CHESSMEN Joint Action
- Availability of medicines is also linked to other areas of the Strategy:
  - Supply chain
  - Data analytics
  - Innovation
- Health system partnership
  - Regulators
  - Health systems
  - Industry




established by EMA during the COVID-19 pandemic on a more permanent footing, while entrusting several

#### **Joint Action - CHESSMEN**

Neither the European Union nor the European Commission can be held responsible for them.







Classified as confidential by the European Medicines Agency





## Thank you for listening

### Further information

See websites for contact details

Heads of Medicines Agencies www.hma.eu European Medicines Agency www.ema.europa.eu

